Published in final edited form as:

J Med Chem. 2012 January 26; 55(2): 567–575. doi:10.1021/jm201650r.

The 2011 E. B. Hershberg Award for Important Discoveries in Medicinally Active Substances: (1S,3S)-3-Amino-4-difluoromethylenyl-1-cyclopentanoic acid (CPP-115), a GABA Aminotransferase Inactivator and New Treatment for Drug Addiction and Infantile Spasms†

Richard B. Silverman*

Department of Chemistry, Department of Molecular Biosciences, Chemistry of Life Processes Institute, Center for Molecular Innovation and Drug Discovery, Northwestern University, Evanston, IL 60208-3113

Introduction

Enzymes are excellent targets for drug design because many diseases, or at least the symptoms of disease, can arise from a deficiency of one specific molecule, an excess of one molecule, infestation of a foreign organism, or aberrant cell growth; all of these etiologies can be modulated by specific enzyme inhibition. Inhibition of an enzyme prevents the conversion of substrate to product, thereby increasing the concentration of the substrate and decreasing the concentration of the product, thereby normalizing a deficiency or excess, respectively, of those particular molecules. By targeting an enzyme essential for the life of a foreign organism or tumor cell, it is possible to destroy that organism or cell or, at least, prevent it from replicating. This Award Lecture Perspective takes advantage of an approach to increase the concentration of a single molecule, namely, γ -aminobutyric acid (GABA), for the treatment of seizure disorders and drug addiction.

The two principal neurotransmitters involved in the regulation of brain neuronal activity are GABA, one of the most widely distributed inhibitory neurotransmitters, and *L*-glutamic acid, an excitatory neurotransmitter.¹ The concentration of GABA is regulated by two pyridoxal 5'-phosphate (PLP)-dependent enzymes, *L*-glutamic acid decarboxylase (GAD), which catalyzes the conversion of *L*-glutamate to GABA, and GABA aminotransferase (GABA-AT), which degrades GABA to succinic semialdehyde (SSA) and converts α -ketoglutarate to *L*-glutamic acid (Figure 1).² When the concentration of GABA diminishes below a threshold level in the brain, convulsions result;³ raising the brain GABA levels terminates the seizure and is an effective approach for the treatment of epilepsy.⁴ Unfortunately, it is futile to take GABA pills to raise the brain GABA levels, because GABA is transported across the blood-brain barrier very poorly⁵ and is effluxed from the brain readily.⁶

Seizures can arise from numerous etiologies; therefore, epilepsy is not a single disease, and the incidence of seizure activity is very prevalent in the world. In fact, when epilepsy is defined broadly as any disease characterized by recurring convulsive seizures, then 1–2% of

†This Award Address was presented at the 242nd National Meeting of the American Chemical Society in Denver, Massachusetts, August 29, 2011.

*Correspondence to the Department of Chemistry Phone: 847-491-5653; Fax: 847-467-1566; Agman@chem.northwestern.edu.

the world population can be classified as having epilepsy.⁷ Consequently, anticonvulsant agents have been sought for centuries. Not until diphenylhydantoin (Dilantin[®]) was introduced onto the drug market almost 60 years ago was any particular anticonvulsant drug widely used.⁸ However, this drug is not generally applicable. In fact, more than one-quarter of epileptic patients worldwide (about 12 million people) do not respond to any marketed anticonvulsant drug.⁵ Therefore, the need for new anticonvulsant drugs is great.⁹

One cause for epilepsy is an imbalance in the GABA/L-glutamate brain levels. A reduction in the concentrations of GABA and/or of the enzyme GAD,¹⁰ which produces GABA, has been implicated not only in the symptoms associated with epilepsy¹¹ but also with several other neurological diseases such as Huntington's chorea,^{12,13} Parkinson's disease,^{14,15} Alzheimer's disease,¹⁶ and tardive dyskinesia.¹⁷ Several approaches have been taken to increase the brain concentrations of GABA. One approach has been to make prodrugs of GABA,^{18,19} but except for progabide, this has not been highly successful. Another approach taken to increase brain GABA levels is the use of a compound that crosses the blood-brain barrier and then inhibits or inactivates GABA-AT, the enzyme that degrades GABA. Inhibition of this enzyme causes a buildup of GABA, assuming that inhibition of GAD is minimal. This effectively dampens excessive neural activity without affecting basal neuronal activity, thereby controlling seizures.²⁰

Numerous competitive inhibitors of GABA-AT, particularly compounds having a similar backbone structure to GABA,²¹ show anticonvulsant activity. A variety of mechanism-based inactivators²² of GABA-AT²³ have been shown to be effective anticonvulsant agents. The most effective of these mechanism-based inactivators as an anticonvulsant agent is 4-aminohex-5-enoic acid (**1**, γ -vinylGABA),²⁴ which has the generic name vigabatrin and trade name Sabril[™]. Vigabatrin is currently marketed as a monotherapy for pediatric patients one month to two years of age with infantile spasms (West's Syndrome) and as an adjunctive therapy for adults with refractory complex partial seizures in 65 countries, including the United States.²⁵ However, 1–3 g of this drug has to be taken daily to be effective. As with all psychotropic drugs, there are a variety of side effects that arise from the use of this drug (see below), which is sold as a racemic mixture; it is not known how many of these side effects arise from the administration of the inactive enantiomer (*R*-isomer).

About 13 years ago it was found that vigabatrin (**1**) possesses another remarkable activity, namely, it prevents cocaine addiction in rats and baboons.²⁶ Self-administration of cocaine by rats decreased or was prevented by vigabatrin administration in a dose-dependent fashion, without affecting the craving for food.²⁷ The current findings indicate that the neurochemical response to cocaine and other drugs of abuse is a sharp increase in dopamine levels in the nucleus accumbens (NAcc),²⁸ which activates the neurons responsible for pleasure and reward responses. The connection between addiction and GABA is that the rise in dopamine and associated addictive behaviors can be antagonized by an increase in the

concentration of GABA. The mechanism of vigabatrin responsible for the prevention of drug addiction would be the same as that for epilepsy, namely, it inactivates GABA-AT, thereby increasing the GABA concentration in the brain (by blocking the degradation of brain GABA). It was shown by positron emission tomography (PET) in primates that vigabatrin inhibits these cocaine-induced dopamine increases.²⁵ Vigabatrin also has been found to have utility in the treatment of a variety of other stimulant addictions,²⁹ specifically in animal models for nicotine,³⁰ methamphetamine, heroin, ethanol,³¹ and combination addictions.³² Vigabatrin treatment also is effective for stimulant addiction in humans,³³ including a randomized, double-blind, placebo-controlled, trial of 103 subjects,³⁴ in which 28.0% of subjects treated with vigabatrin achieved abstinence compared to 7.5% of subjects treated with placebo.

The acceptance of vigabatrin for the treatment of both epilepsy and as a potential treatment for stimulant addiction has been hampered primarily by concerns about abnormalities of the peripheral visual field (visual field defects or VFDs), resulting from retinal damage, in 25–50% of patients following chronic administration of vigabatrin.³⁵ The development of VFDs seems to result from prolonged exposure to high doses of vigabatrin.³⁶ The mechanism leading to the VFDs is not known, but it remains an active area of research. VFDs might occur as a direct toxic effect of vigabatrin, from the inactive enantiomer (*R*-isomer), from elevated GABA levels as a result of inactivation of GABA-AT, as a consequence of an enzymatically produced byproduct (a metabolite) from one of the enzyme inactivation mechanisms, off-target activities, or some combination of these potential mechanisms. Although it has been hypothesized that elevated GABA levels might be involved in vigabatrin-elicited retinal damage,³⁷ it has been demonstrated that in albino rats acute vigabatrin exposure damages the outer retina by a GABA-independent and vigabatrin-specific mechanism, resulting in sensitization of photoreceptors to light-induced damage.³⁸ In this case, it is probable that reactive oxygen species are involved since they participate in light-mediated retinal toxicity.³⁹ If the prevailing belief that VFDs arise from prolonged exposure to large doses of vigabatrin is correct, and if much lower doses of an alternative drug can be used, this could dramatically diminish, if not eliminate, the resulting VFDs.

To design an alternative to vigabatrin, a mechanism-based inactivator,⁴⁰ it is important to understand how that compound inhibits GABA-AT. A mechanism-based inactivator is an unreactive compound whose structure is related to that of the substrate for the target enzyme, which converts the inactivator into a species that leads to inactivation of that enzyme, prior to escape of that species from the active site. Therefore, the design of a mechanism-based inactivator requires knowledge of the substrate(s) for and mechanism of the target enzyme.

GABA-AT is a dimeric enzyme, each subunit containing an active site pyridoxal 5'-phosphate (PLP) coenzyme; however, the two PLP binding sites are nonequivalent.⁴¹ Following inactivation with one equivalent of inactivator, it is possible to incorporate a second coenzyme molecule and regain activity. This may explain why some inactivators become incorporated at the level of one equivalent per enzyme dimer and others incorporate two equivalents per dimer. The primary sequence of GABA-AT has been deduced from the cDNA of pig brain⁴² and from peptide fragments of the pig liver enzyme.⁴³ In 1999 the X-ray crystal structure of pig liver GABA-AT was reported to 3.0 Å resolution by the Schirmer group in Basel.⁴⁴ A 1.9 Å resolution crystal structure with one of our inactivators bound also has been reported.⁴⁵

The mechanism of GABA aminotransferase is shown in Scheme 1. Following Schiff base formation (**2**), tautomerization gives the aldimine (**3**), which is hydrolyzed to succinic semialdehyde (SSA) and pyridoxamine 5'-phosphate (PMP). At this point the enzyme is

inactive, as the coenzyme is in the wrong oxidation state. α -Ketoglutarate (α -KG) then converts the PMP back to PLP with concomitant formation of L-glutamate. On the basis of the substrate mechanism, we investigated the inactivation mechanism of vigabatrin and found that it inactivates GABA-AT by at least two mechanisms, a Michael addition mechanism following tautomerization to ketimine **4** (Scheme 2, pathway a, leading to **5**) and an enamine mechanism following tautomerization through the vinyl double bond and release of enamine **6** (pathway b, leading to **7**).⁴⁶ These two pathways were shown to occur in about a 70:30 ratio, respectively. A crystal structure of inactivated GABA-AT to 2.3 Å resolution confirmed the Michael addition adduct structure (**5**)⁴⁷ (Figure 2).

As noted above, a serious drawback to the use of vigabatrin is retinal toxicity produced in a large percentage of patients using it chronically. One suggested hypothetical cause for the retinal damage might be the formation of a metabolite of vigabatrin. During our studies on the mechanism of inactivation of GABA-AT by vigabatrin, it was found that ketimine **4** underwent partial hydrolysis to the corresponding α,β -unsaturated ketone (**8**), a reactive electrophile, and PMP. Possibly that electrophile, released in the brain, could cause retinal toxicity. Hydrolysis of enamine **6**, however, would give saturated ketone **9**, which would not be highly electrophilic.

Therefore, if the Michael addition pathway could be bypassed in favor of the minor enamine pathway, electrophile **8** could be avoided. An energy minimized molecular model of vigabatrin bound to PLP within GABA-AT (Figure 3A) showed that it was set up for Lys-329 deprotonation, but following tautomerization, the vinyl double bond was in the wrong orientation for Michael addition to occur. Bond rotation was necessary to permit Michael addition (Figure 3B). Therefore, prevention of bond rotation should block the Michael addition pathway but not the enamine pathway. This is readily accomplished with conformationally-restricted analogs, such as **10** and **11**.⁴⁸ Both of these compounds were found to be irreversible inactivators of GABA-AT; the k_{inact}/K_I for **10** was twice that of **11**, so mechanistic studies were focused on **10**. If the Michael addition pathway occurred with **10**, then the coenzyme would be in the PMP form (Scheme 3, pathway a); if the enamine mechanism occurred, then, after denaturation, modified coenzyme **12** would result (Scheme 3, pathway b). Modified coenzyme **12** was synthesized, the PLP in GABA-AT was removed and replaced with [³H]PLP, then the tritiated enzyme was inactivated with **10** and denatured. HPLC of the supernatant revealed only **12**, no PMP, indicating that the Michael addition pathway was blocked, and only the enamine pathway had occurred. Unfortunately, **10** was not very potent, so an alternative way of preventing the formation of an electrophilic product was sought.

An alternative approach could be to allow the Michael addition pathway to proceed, but design the molecule so that the intermediate ketimine undergoes covalent reaction with Lys-329 much faster than hydrolysis of the ketimine can occur. To accomplish that, a compound was designed having a double bond that was oriented toward Lys-329 after Schiff base formation with the PLP⁴⁹ (**13**, Figure 4). Compound **13** was a time-dependent inactivator of GABA-AT, but only after a lag in time, suggesting that the compound was converted to a product (**14**), which escaped from the active site, built up in solution, then returned to cause inactivation. When a good nucleophile (β -mercaptoethanol) was added to the incubation mixture to trap any electrophiles released from the enzyme, there was no inactivation, supporting this hypothesis. Therefore, a more reactive electrophile was sought. Michael acceptors become more reactive when electron-withdrawing groups are added to the terminus of the double bond. Because fluorine is strongly electron withdrawing, yet relatively small, **13** was modified by the substitution of two fluorine atoms at the alkene terminus to give **15**.⁴⁷ Compound **15** (now referred to as **CPP-115**)⁵⁰ was found to inactivate GABA-AT instantaneously, even in the presence of β -mercaptoethanol, with a K_I of 9.7 μM , whereas vigabatrin had a K_I of 850 μM under the same conditions. The k_{inact} values for **15** (**CPP-115**) and vigabatrin were 0.50 min^{-1} and 0.24 min^{-1} , respectively. Therefore, **15** was 187 times more efficient an inactivator of GABA-AT than vigabatrin (k_{inact}/K_I 52 $\text{mM}\cdot\text{min}^{-1}$ for **15** and k_{inact}/K_I 0.28 $\text{mM}\cdot\text{min}^{-1}$ for vigabatrin).

Some off-target activities of **15** were investigated. Vigabatrin is known to inhibit alanine aminotransferase in vitro⁵¹ and in vivo,⁵² which might account for some of its side effects. It also inactivates aspartate aminotransferase.⁵³ We have found that **15** neither inactivates (**A**) nor inhibits (**B**) alanine aminotransferase and aspartate aminotransferase (data not shown) up to 6 mM concentration (Figure 5).⁵⁰

To determine if **15** has GABAergic properties, its binding to a variety of GABA binding proteins was investigated.⁵¹ Compound **15** does not bind to human GABA transporters hGAT-1, hBGAT-1, hGAT-2, and hGAT-3, to mouse GABA transporters mGAT-1, mGAT-2, mGAT-3, mGAT-4, or to neurons or astrocytes up to 1 mM concentration. At concentrations up to 100 μM , **15** does not displace GABA (IC_{50} in low nM range) from GABA_A or GABA_B receptors, nor is it an agonist or antagonist of the GABA_C receptor.⁵¹ Therefore, it appears that **15** does not exhibit GABAergic activities.

As noted above, drug addiction results from the release of dopamine when an addictive substance is ingested. The effects of vigabatrin and **15** on the release of dopamine in the

nucleus accumbens (NAcc) in freely moving rats were determined. As shown in Figure 6, the dopamine concentration increases by 550% (relative to control) in the NAcc after 20 mg/kg cocaine was administered. Treatment with 300 mg/kg of vigabatrin reduced the dopamine concentration to about 330% of basal level, but only 1 mg/kg of **15** was needed to reduce the dopamine levels to 250% of basal level.⁵¹ Therefore, **15** is > 300 times more potent than vigabatrin for reducing dopamine levels in the NAcc.

Another measure of dopamine release can be made by in vivo micro-positron emission tomography (microPET) imaging.⁵⁴ Dopamine can release [¹¹C]-raclopride from NAcc, so treatment of rats with cocaine shows the displacement of [¹¹C]-raclopride as a result of the released dopamine (Figure 7, cocaine panel). The same experiment with either vigabatrin at 300 mg/kg or **15** at 0.5 mg/kg does not cause release of [¹¹C]-raclopride, indicating that not sufficient dopamine was released to displace the [¹¹C]-raclopride. Therefore, **15** is 600 times more potent than vigabatrin in this experiment.

The standard paradigm for measurement of addiction potential of drugs in animals is conditioned place preference.⁵⁵ There are two different colored chambers. Some animals are placed into one and given an injection of an addictive substance. Other animals are placed in the other chamber and are given an injection of saline. The next day the animals are reversed. This process continues for 10 days, so they are trained to associate one chamber with the addictive substance and the other with saline. On the test day all animals have free access, in a drug free state, to both chambers. What generally happens is they exhibit a conditioned place preference for the addictive substance-paired chamber and just sit in there. The beauty of this paradigm is that animals are tested in a drug-free state and, therefore, make a choice in the absence of any acute drug effects. For **15** and vigabatrin the animals were first trained with cocaine. Then when **15** at 1 mg/kg (or vigabatrin at 300 mg/kg) was administered with cocaine, the animals reverted to no place preference (Table 1), indicating that they no longer were addicted. Once again, **15** was 300 times more potent than vigabatrin. A serious problem with drug addiction is that following a treatment program the former addict may be subjected to sensory reminders of the addiction, which can lead to a return to the substance abuse. The above experiment demonstrates that, even when faced with a sensory reminder, the animals do not revert to their addictive desire.

The effect of **15** on infantile spasms in rats also was investigated.⁵⁶ Infantile spasms is a severe form of epilepsy, leading to cognitive deterioration, mental retardation, other serious seizures, and mortality.⁵⁷ The incidence is about one in 2000–4000 live births, which accounts for about 30% of childhood epilepsies. There are two drugs that have been used to treat infantile spasms, adrenocorticotrophic hormone (ACTH) and vigabatrin, but both cause serious side effects.⁵⁵ Because of the ineffectiveness of ACTH, vigabatrin was approved in the United States in 2009 for infantile spasms, despite the associated visual field defect side effect.⁵⁸ In a multiple-hit rat model for infantile spasms,⁵⁹ which is refractory to ACTH, **15** suppressed spasms at doses of 0.1–1 mg/kg, 100 times lower than doses of vigabatrin, with more sustained effect and better tolerance than vigabatrin. Therefore, **15** has a much larger margin of safety than vigabatrin. Compound **15** was granted orphan drug designation by the FDA for the treatment of infantile spasms.

Oral gavage administration of **15** to rats at a dose of 2, 6, and 20 mg/kg/day for 28 days was well tolerated at 2 and 6 mg/kg/day and resulted in no clinical observations or changes in body weight or food consumption. Oral gavage administration of **15** to beagle dogs at dose levels of 0.7, 2.3, and 7 mg/kg/day for 28 days was well tolerated at all dose levels.

Finally, the effect of **15** and vigabatrin on retinal damage was determined. The effective dose for infantile spasms in rats using vigabatrin is 300 mg/kg/day. At 200 mg/kg, roughly

the effective dose, after 45 days of treatment there was a 30–60% electroretinographic loss. The effective dose in rats for **15** is 0.5–1 mg/kg/day. At 20 mg/kg after 45 days there was only a 5–30% electroretinographic loss. But this is 20–40 times the effective dose, so at the effective dose, there should be an insignificant retinal loss.

In conclusion, on the basis of our early studies of the mechanism of inactivation of GABA-AT by vigabatrin,⁴⁶ we found that a by-product of inactivation was a reactive electrophile, which we wanted to prevent from being produced. A conformationally-rigid analog of vigabatrin was synthesized that avoided the Michael addition inactivation pathway (Scheme 2, pathway a), which was responsible for the generation of the electrophile.⁴⁸ Although this was successful, the inactivator had low potency. An alternative approach was investigated, by which the inactivator was designed to proceed via the Michael addition pathway, but the intermediate would encourage rapid covalent reaction by the enzyme without release of an electrophilic species. This approach looked promising, but the intermediate was not reactive enough, and an electrophile was still released. The compound was modified to increase its reactivity, leading to **15**, which was 187 times more potent than vigabatrin in vitro and 300–600 times more potent in vivo in a rat model for drug addiction and >100 times more effective in the treatment of infantile spasms in a rat model. At 20–40 times greater dose of **15** than was needed to treat drug addiction and infantile spasms, there was much less retinal damage than administration of vigabatrin at its effective dose. Compound **15** has been licensed to Catalyst Pharmaceutical Partners, Inc., which has begun Phase I clinical trials.

Acknowledgments

The author is grateful to the graduate students (Yue Pan, Shrenik Nanavati, and Hyunbeom Lee), postdoc (Sun Choi), and collaborators (Tilman Schirmer and Paola Storici, University of Basel for X-ray crystallography; Stephen Dewey, Wynne K. Schiffer, Jonathan D. Brodie, and Madina R. Gerasimov, Brookhaven National Laboratory and North Shore Long Island Jewish Health System for the drug addiction experiments; Hans Bräuner-Osborne, Arne Schousboe, Trine Kvist, Petrine Wellendorph, and Karsten K. Madsen, University of Copenhagen for GABA transporter and GABA_A and GABA_B studies; Mary Chebib and Elena Pera, University of Sydney for GABA_C experiments; Cheryl M. Craft, University of Southern California for retina studies; Aristeia Galanopoulou, Stephen W. Briggs, Tomonori Ono, and Solomon L. Moshé, Albert Einstein College of Medicine for studies related to infantile spasms; and Steven R. Miller, Catalyst Pharmaceutical Partners for managing preclinical studies). The author is grateful to the National Institutes of Health (GM066132 and DA030604) for financial support.

Abbreviations used

ACTH	adrenocorticotrophic hormone
GABA	γ-aminobutyric acid
GABA-AT	GABA aminotransferase
GAD	L-glutamic acid decarboxylase
α-KG	α-ketoglutarate
NAcc	nucleus accumbens
PET	positron emission tomography
PLP	pyridoxal 5'-phosphate
PMP	pyridoxamine 5'-phosphate
SSA	succinic semialdehyde
VFD	visual field defect

References

1. McGeer, EG.; McGeer, PL.; Thompson, S. GABA and Glutamate Enzymes. In: Hertz, L.; Kvamme, E.; McGeer, EG.; Schousboe, A., editors. *Glutamine, Glutamate, and GABA in the Central Nervous System*. Liss; New York: 1983. p. 3-17.
2. Baxter CF, Roberts E. The γ -aminobutyric acid- α -ketoglutaric acid transaminase of beef brain. *J Biol Chem*. 1958; 233:1135–1139. [PubMed: 13598746]
3. Karlsson A, Fonnum F, Malthé-Sørensen D, Storm-Mathisen J. Effect of the convulsive agent 3-mercaptopropionic acid on the levels of GABA, other amino acids and glutamate decarboxylase in different regions of the rat brain. *Biochem Pharmacol*. 1974; 23:3053–3061. [PubMed: 4154755]
4. Gale K. GABA in epilepsy: the pharmacologic basis. *Epilepsia*. 1989; 30(Suppl 3):S1–S11. [PubMed: 2548836]
5. Takanaga H, Ohtsuki S, Hosoya K-i, Terasaki T. GAT2/BGT-1 as a system responsible for the transport of γ -aminobutyric acid at the mouse blood-brain barrier. *J Cerebral Blood Flow Metab*. 2001; 21(10):1232–1239.
6. Kakee A, Takanaga H, Terasaki T, Naito M, Tsuruo T, Sugiyama Y. Efflux of a suppressive neurotransmitter, GABA, across the blood-brain barrier. *J Neurochem*. 2001; 79:110–118. [PubMed: 11595763]
7. (a) <http://www.epilepsyfoundation.org/about/statistics.cfm> Rogawski MA, Porter RJ. Antiepileptic drugs: pharmacological mechanisms and clinical efficacy with consideration of promising developmental stage compounds. *Pharmacol Rev*. 1990; 42:223–286. [PubMed: 2217531]
8. Woodbury, DM.; Penry, JK.; Schmidt, RP. *Antiepileptic Drugs*. Raven Press; New York: 1972. Bromides.
9. Czapinski P, Blaszczyk B, Czuczwar SJ. Mechanisms of action of antiepileptic drugs. *Curr Top Med Chem*. 2005; 5:3–14. [PubMed: 15638774]
10. (a) Petroff OAC, Rothman DL. Measuring human brain GABA in vivo: effects of GABA-transaminase inhibition with vigabatrin. *Mol Neurobio*. 1998; 16(1):97–121. (b) Horton RW. GABA and seizures induced by inhibitors of glutamic acid decarboxylase. *Brain Res Bull*. 1980; 5(Suppl 2):605–608.
11. (a) Yogeewari P, Sriram D, Vaigundaragavendran J. The GABA shunt: an attractive and potential therapeutic target in the treatment of epileptic disorders. *Curr Drug Metab*. 2005; 6:127–139. [PubMed: 15853764] (b) Bakay RAE, Harris AB. Neurotransmitter, receptor and biochemical changes in monkey cortical epileptic foci. *Brain Res*. 1981; 206:387–404. [PubMed: 6111378] (c) Loyd, KG.; Munari, C.; Bossi, L.; Stoeffels, C.; Talairach, J.; Morselli, PL. Biochemical evidence for the alterations of GABA-mediated synaptic transmission in pathological brain tissue (stereo EEG or morphological definition) from epileptic patients. In: Morselli, PL.; Loescher, W.; Loyd, KG., editors. *Neurotransmission, Seizures, Epilepsy*. Raven Press; New York: 1981. p. 325-338.
12. (a) Perry TL, Hansen S, Lesk D, Kloster M. Amino acids in plasma, cerebrospinal fluid, and brain of patients with Huntington's chorea. *Adv Neurol*. 1972; 1:609–618. (b) McGeer, PL.; McGeer, EG. The GABA system and function of the basal ganglia: Huntington's disease. In: Roberts, E.; Chase, TN.; Tower, DB., editors. *GABA in Nervous System Function*. Raven Press; New York: 1976. p. 487-495.
13. (a) Butterworth J, Yates CM, Simpson J. Phosphate-activated glutaminase in relation to Huntington's disease and agonal state. *J Neurochem*. 1983; 41:440–447. [PubMed: 6223989] (b) Spokes EGS. Brain temperature after death. *Adv Exp Med Biol*. 1978; 123:461–473. [PubMed: 160193] (c) Wu JY, Bird ED, Chen MS, Huang WM. Abnormalities of neurotransmitter enzymes in Huntington's chorea. *Neurochem Res*. 1979; 4:575–586. [PubMed: 40150] (d) Iversen LL, Bird ED, Mackay AVP, Rayner CN. Analysis of glutamate decarboxylase in post-mortem brain tissue in Huntington's chorea. *J Psychiat Res*. 1974; 11:255–256. [PubMed: 4282387]
14. Nishino N, Fujiwara H, Noguchi-Kuno SA, Tanaka C. GABA receptor but not muscarinic receptor density was decreased in the brain of patients with Parkinson's disease. *Jpn J Pharmacol*. 1988; 48:331–339. [PubMed: 2851679]
15. (a) Maker HS, Weiss C, Weissbarth S, Silides DJ, Whetsell W. Regional activities of metabolic enzymes and glutamate decarboxylase in human brain. *Ann Neurol*. 1981; 10:377–383. [PubMed: 7316490] (b) Rinne UK, Laaksonen H, Riekkinen P, Sonninen V. Brain glutamic acid

- decarboxylase activity in Parkinson's disease. *Eur Neurol.* 1974; 12:13–19. [PubMed: 4412241]
- (c) McGeer PL, McGeer EG, Wada JA, Jung E. Effects of globus pallidus lesions and Parkinson's disease on brain glutamic acid decarboxylase. *Brain Res.* 1971; 32:425–431. [PubMed: 4944072]
16. (a) Aoyagi T, Wada T, Nagai M, Kojima F, Harada S, Takeuchi T, Takahashi H, Hirokawa K, Tsumita T. Increased g-aminobutyrate aminotransferase activity in brain of patients with Alzheimer's disease. *Chem Pharm Bull.* 1990; 38:1748–1749. [PubMed: 2208389] (b) Davies P. Neurotransmitter-related enzymes in senile dementia of the Alzheimer type. *Brain Res.* 1979; 171:319–327. [PubMed: 37989] (c) Perry EK, Gibson PH, Blessed G, Perry RH, Tomlinson BE. Neurotransmitter enzyme abnormalities in senile dementia. Choline acetyltransferase and glutamic acid decarboxylase activities in necropsy brain tissue. *J Neurol Sci.* 1977; 34:247–265. [PubMed: 144789] (d) Bowen DM, White P, Flack RHA, Smith CB, Davison NA. Brain-decarboxylase activities as indices of pathological change in senile dementia. *Lancet.* 1974; 1:1247–1249. [PubMed: 4134959] (e) Kodama K, Kaitani H, Nanba M, Kondo T, Mikame F, Yoshida H, Sato K, Yanaihara N. Neurotransmitter analogs in body fluids of patients with dementia. *Shinkei Kagaku.* 1981; 20:496.
 17. Gunne LM, Haeggstroem JE, Sjöquist B. Association with persistent neuroleptic-induced dyskinesia of regional changes in brain GABA synthesis. *Nature (London).* 1984; 309:347–349. [PubMed: 6727989]
 18. Kaplan JP, Raizon BM, Desarmenien M, Feltz P, Headley PM, Worms P, Lloyd KG, Bartholini G. New anticonvulsants: Schiff bases of gamma-aminobutyric acid and gamma-aminobutyramide. *J Med Chem.* 1980; 23:702–706. [PubMed: 7392039]
 19. (a) Shashoua VE, Jacob JN, Ridge R, Campbell A, Baldasarini RJ. Gammaaminobutyric acid esters. 1. Synthesis, brain uptake, and pharmacological studies of aliphatic and steroid esters of gamma-aminobutyric acid. *J Med Chem.* 1984; 27:659–664. [PubMed: 6716404] (b) Jacob JN, Hesse GW, Shashoua VE. Synthesis, brain uptake, and pharmacological properties of a glyceryl lipid containing GABA and the GABA-T inhibitor gamma-vinyl-GABA. *J Med Chem.* 1990; 33:733–737. [PubMed: 2299639]
 20. Waterhouse EJ, Mims Kimberly N, Gowda SN. Treatment of refractory complex partial seizures: role of vigabatrin. *Neuropsychiatr Dis Treat.* 2009; 5:505–515. [PubMed: 19851518]
 24. (a) Johnston GAR, Curtis DR, Beart PM, Game CJA, McColloch RM, Twichin B. Cis- and trans-4-aminocrotonic acid as GABA analogues of restricted conformation. *J Neurochem.* 1975; 24:157–160. [PubMed: 234147] (b) Schon F, Kelly JS. The characterisation of [³H]GABA uptake into the satellite glial cells of rat sensory ganglia. *Brain Res.* 1974; 66:289–300. (c) Johnston GAR, Stephanson AL, Twichin B. Piperazic acid and related compounds as inhibitors of GABA uptake in rat brain slices. *J Pharm Pharmacol.* 1977; 29:240–241. [PubMed: 17676] (d) Brehm L, Hjeds H, Krogsgaard-Larsen P. The structure of muscimol, a GABA analogue of restricted conformation. *Acta Chem Scand.* 1972; 26:1298–1299. [PubMed: 5079744] (e) Krogsgaard-Larsen P, Johnston GAR, Lodge D, Curtis DR. A new class of GABA agonist. *Nature (London).* 1977; 268:53–55. [PubMed: 196200] (f) Beart PM, Curtis DR, Johnston GAR. 4-aminotetrolic acid: new conformational-restricted analogue of γ -aminobutyric acid. *Nature (New Biol).* 1971; 234:80–81. [PubMed: 5288736] (g) Beart PM, Johnston GAR. GABA [γ -aminobutyric acid] uptake in rat brain slices. Inhibition by GABA analogs and by various drugs. *Aust J Chem.* 1972; 25:1359–1361.
 22. (a) Silverman, RB. *Mechanism-Based Enzyme Inactivation: Chemistry and Enzymology.* Vol. I and II. CRC Press; Boca Raton, FL: 1988. (b) Silverman RB. Mechanism-based enzyme inactivators. *Methods Enzymol.* 1995; 249:240–283. [PubMed: 7791614]
 23. Nanavati SM, Silverman RB. Design of potential anticonvulsant agents: mechanistic classification of GABA aminotransferase inactivators. *J Med Chem.* 1989; 32:2413–2421. [PubMed: 2681782]
 24. Lippert B, Metcalf BW, Jung MJ, Casara P. 4-amino-hex-5-enoic acid, a selective catalytic inhibitor of 4-aminobutyric-acid aminotransferase in mammalian brain. *Eur J Biochem.* 1977; 74:441–445. [PubMed: 856582]
 25. (a) Tassinari CA, Michelucci R, Ambrosetto G, Salvi F. Double-blind study of vigabatrin in the treatment of drug-resistant epilepsy. *Arch Neurol.* 1987; 44:907–910. [PubMed: 2887152] (b) Browne TR, Mattson RJ, Penry JK, Smith DB, Treiman DM, Wilder BJ, Ben-Menachem E, Miketta RM, Sherry KM, Szabo GK. A multicentre study of vigabatrin for drug-resistant epilepsy. *Br J Clin Pharmacol.* 1989; 27:95S–100S. [PubMed: 2667606] (c) Sivenius MR, Ylinen A, Murros

- K, Matilainen R, Riekkinen P. Double-blind dose reduction study of vigabatrin in complex partial epilepsy. *Epilepsia*. 1987; 28:688–692. [PubMed: 3319536]
26. Dewey SL, Morgan AE, Ashby CR Jr, Horan B, Kushner SA, Logan J, Volkow ND, Fowler JS, Gardner EL, Brodie JD. A novel strategy for the treatment of cocaine addiction. *Synapse*. 1998; 30:119–129. [PubMed: 9723781]
27. Kushner SA, Dewey SL, Kornetsky C. The irreversible γ -aminobutyric acid (GABA) transaminase inhibitor γ -vinyl-GABA blocks cocaine self-administration in rats. *J Pharmacol Exp Ther*. 1999; 290:797–802. [PubMed: 10411594]
28. Dewey, Stephen L.; Morgan, Alexander E.; Ashby, Charles R., Jr; Bryan, Horan; Kushner, Stephanie A.; Logan, Jean; Volkow, Nora D.; Fowler, Joanna S.; Gardner, Eliot L.; Brodie, Jonathan D. A novel strategy for the treatment of cocaine addiction. *Synapse*. 1998; 30(2):119–129. [PubMed: 9723781]
29. (a) Karila L, Gorelick D, Weinstein A, Noble F, Benyamina A, Coscas S, Blecha L, Lowenstein W, Martinot JL, Reynaud M, Lepine JP. New treatments for cocaine dependence: a focused review. *Internat J Neuropsychopharmacol*. 2008; 11(3):425–438. (b) Peng XQ, Li X, Gilbert JG, Pak AC, Ashby CR, Brodie JD, Dewey SL, Gardner EL, Xi ZX. Gamma-vinyl GABA inhibits cocaine-triggered reinstatement of drug-seeking behavior in rats by a non-dopaminergic mechanism. *Drug Alcohol Depend*. 2008; 97(3):216–225. [PubMed: 18063319]
30. Dewey SL, Brodie JD, Gersimov M, Horan B, Gardner EL, Ashby CR Jr. A pharmaceutical strategy for the treatment of nicotine addiction. *Synapse*. 1999; 31(1):76–86. [PubMed: 10025686]
31. Gersimov MR, Ashby CR Jr, Gardner EL, Mills MJ, Brodie JD, Dewey SL. Gamma-vinyl GABA inhibits methamphetamine, heroin, or ethanol-induced increases in nucleus accumbens dopamine. *Synapse*. 1999; 34(1):11–19. [PubMed: 10459167]
32. Stromberg MF, Mackler SA, Volpicelli JR, O'Brien CP, Dewey SL. The effect of gamma-vinyl-GABA on the consumption of concurrently available oral cocaine and ethanol in the rat. *Pharmacol Biochem Behav*. 2001; 68:291–299. [PubMed: 11267634]
33. (a) Brodie JD, Figueroa E, Dewey SL. Treating cocaine addiction: from preclinical to clinical trial experience with γ -vinyl GABA. *Synapse*. 2003; 50(3):261–265. [PubMed: 14515344] (b) Brodie JD, Figueroa E, Laska EM, Dewey SL. Safety and efficacy of γ -vinyl GABA (GVG) for the treatment of methamphetamine and/or cocaine addiction. *Synapse*. 2005; 55(2):122–125. [PubMed: 15543630]
34. Brodie JD, Case BG, Figueroa E, Dewey SL, Robinson JA, Wanderling JA, Laska EM. Randomized, double-blind, placebo-controlled trial of vigabatrin for the treatment of cocaine dependence in Mexican parolees. *Am J Psychiatry*. 2009; 166:1269–1277. [PubMed: 19651710]
35. (a) Willmore LJ, Abelson MB, Ben-Menachem E, Pellock JM, Shields D. Vigabatrin: 2008 Update. *Epilepsia*. 2009; 50(2):163–173. [PubMed: 19230067] (b) Wild JM, Chiron C, Ahn H, Baulac M, Bursztyn J, Gandolfo E, Goldberg I, Goni FJ, Mercier F, Nordmann JP, Safran AB, Schiefer U, Perucca E. Visual field loss in patients with refractory partial epilepsy treated with vigabatrin. *CNS Drugs*. 2009; 23(11):965–982. [PubMed: 19845417]
36. Fechtner RD, Khouri AS, Figueroa E, Ramirez M, Federico M, Dewey SL, Brodie JD. Short-term treatment of cocaine and/or methamphetamine abuse with vigabatrinocular safety pilot results. *Arch Ophthalmol*. 2006; 124:1257–1262. [PubMed: 16966620]
37. Duboc A, Hanoteau N, Simonutti M, Rudolf G, Nehlig A, Sahel JA, Picaud S. Vigabatrin, the GABA-transaminase inhibitor, damages cone photoreceptors in rats. *Ann Neurol*. 2004; 55(5):695–705. [PubMed: 15122710]
38. Izumi Y, Ishikawa M, Benz AM, Izumi M, Zorumski CF, Thio LL. Acute vigabatrin retinotoxicity in albino rats depends on light but not GABA. *Epilepsia*. 2004; 45(9):1043–1048. [PubMed: 15329067]
39. Roberts JE. Ocular phototoxicity. *J Photochem Photobiol B*. 2001; 64(2–3):136–143. [PubMed: 11744400]
40. (a) Silverman RB. Mechanism-based enzyme inactivators. *Methods Enzymol*. 1995; 249:240–283. [PubMed: 7791614] (b) Silverman, RB. Mechanism-Based Enzyme Inactivation: Chemistry and Enzymology. Vol. I and II. CRC Press; Boca Raton, FL: 1988.

41. Churchich JE, Moses U. 4-Aminobutyrate aminotransferase. The presence of nonequivalent binding sites. *J Biol Chem.* 1981; 256:1101–1104. [PubMed: 7451492]
42. Kwon OS, Park J, Churchich JE. Brain 4-aminobutyrate aminotransferase. isolation and sequence of a cDNA encoding the enzyme. *J Biol Chem.* 1992; 267:7215–7216. [PubMed: 1559966]
43. De Biase D, Maras B, Bossa F, Barra D, John RA. Protein structure of pig liver 4-aminobutyrate aminotransferase and comparison with a cDNA-deduced sequence. *Eur J Biochem.* 1992; 208:351–357. [PubMed: 1521531]
44. Storici P, Capitani G, De Biase D, Moser M, John RA, Jansonius JN, Schirmer T. Crystal structure of GABA-aminotransferase, a target for antiepileptic drug therapy. *Biochemistry.* 1999; 38:8628–8634. [PubMed: 10393538]
45. Storici P, Qiu J, Schirmer T, Silverman RB. Mechanistic crystallography. Mechanism of inactivation of γ -aminobutyric acid aminotransferase by (1*R*,3*S*,4*S*)-3-amino-4-fluorocyclopentane-1-carboxylic acid as elucidated by crystallography. *Biochemistry.* 2004; 43:14057–14063. [PubMed: 15518554]
46. Nanavati SM, Silverman RB. Mechanisms of inactivation of γ -aminobutyric acid aminotransferase by the antiepilepsy drug γ -vinyl GABA (vigabatrin). *J Am Chem Soc.* 1991; 113:9341–9349.
47. Storici P, De Biase D, Bossa F, Bruno S, Mozzarelli A, Peneff C, Silverman RB, Schirmer T. Structures of γ -aminobutyric acid (GABA) aminotransferase, a pyridoxal 5'-phosphate and [2Fe-2S] cluster containing enzyme, complexed with γ -ethynyl GABA and with the antiepilepsy drug vigabatrin. *J Biol Chem.* 2004; 279:363–373. [PubMed: 14534310]
48. Choi S, Storici P, Schirmer T, Silverman RB. Design of a conformationally-restricted analogue of the antiepilepsy drug vigabatrin that directs its mechanism of inactivation of γ -aminobutyric acid aminotransferase. *J Am Chem Soc.* 2002; 124:1620–1624. [PubMed: 11853435]
49. Pan Y, Qiu J, Silverman RB. Design, synthesis, and biological activity of a difluoro-substituted, conformationally-rigid vigabatrin analogue as a potent γ -aminobutyric acid aminotransferase inhibitor. *J Med Chem.* 2003; 46:5292–5293. [PubMed: 14640537]
50. Pan Y, Gerasimov MR, Kvist T, Wellendorph P, Madsen KK, Pera E, Lee H, Schousboe A, Chebib M, Bräuner-Osborne H, Craft CM, Brodie JD, Schiffer WK, Dewey SL, Miller SR, Silverman RB. (1*S*,3*S*)-3-amino-4-difluoromethylenyl-1- cyclopentanoic acid (CPP-115), a potent γ -aminobutyric acid aminotransferase inactivator for the treatment of cocaine addiction. *J Med Chem.* 2012 in press.
51. Okumura H, Omote M, Takeshita S. In vitro effects of the novel antiepileptic agent vigabatrin on alanine aminotransferase and aspartate aminotransferase activities in rat serum. *Arz-Forsch.* 1996; 46(5):459–462.
52. (a) Richens A, Mcewan JR, Deybach JC, Mumford JP. Evidence for both in vivo and in vitro interaction between vigabatrin and alanine transaminase. *British Journal of Clinical Pharmacology.* 1997; 43(2):163–168. [PubMed: 9131948] (b) Foletti GB, Delisle MC, Bachmann C. Reduction of plasma alanine aminotransferase during vigabatrin treatment. *Epilepsia.* 1995; 36(8):804–9. [PubMed: 7635099] (c) Williams A, Sekaninova S, Coakley J. Suppression of elevated alanine aminotransferase activity in liver disease by vigabatrin. *J Paediatr Child H.* 1998; 34(4):395–7.
53. John RA, Jones ED, Fowler LJ. Enzyme-induced inactivation of transaminases by acetylenic and vinyl analogs of 4-aminobutyrate. *Biochem J.* 1979; 177(2):721–8. [PubMed: 435262]
54. Dewey SL, Morgan AE, Ashby CR Jr, Horan B, Kushner SA, Logan J, Volkow ND, Fowler JS, Gardner EL, Brodie JD. A novel strategy for the treatment of cocaine addiction. *Synapse.* 1998; 30:119–129. [PubMed: 9723781]
55. (a) DeMarco A, Dalal RM, Pai J, Aquilina SD, Mullapudi U, Hammel C, Kothari SK, Kahanda M, Liebling CNB, Patel V, Schiffer WK, Brodie JD, Dewey SL. Racemic gamma vinyl-GABA (R,S-GVG) blocks methamphetamine-triggered reinstatement of conditioned place preference. *Synapse.* 2009; 63(2):87–94. [PubMed: 19016239] (b) Carboni E, Vacca C. Conditioned place preference: A simple method for investigating reinforcing properties in laboratory animals. *Meth Mol Med.* 2003; 79:481–498. (Drugs of Abuse). (c) Tzschentke TM. Measuring reward with the conditioned place preference paradigm: a comprehensive review of drug effects, recent progress and new issues. *Prog Neurobiol (Oxford).* 1998; 56(6):613–672.
56. Briggs, SW.; Ono, T.; Moshé, SL.; Galanopoulou, AS. presented at the American Epilepsy Society Meeting; 2011.

57. (a) Chudomelova L, Scantlebury MH, Raffo E, Coppola A, Betancourth D, Galanopoulou AS. Modeling new therapies for infantile spasms. *Epilepsia*. 2010; 51(Suppl 3):27–33. [PubMed: 20618396] (b) Tsao C-Y. Current trends in the treatment of infantile spasms. *Neuropsychiat Dis Treat*. 2009; 5:289–299.
58. Lerner JT, Salamon N, Sankar R. Clinical profile of vigabatrin as monotherapy for treatment of infantile spasms. *Neuropsychiat Dis Treat*. 2010; 6:731–740.
59. Raffo E, Coppola A, Ono T, Briggs SW, Galanopoulou AS. A pulse rapamycin therapy for infantile spasms and associated cognitive decline. *Neurobiol Dis*. 2011; 43(2):322–329. [PubMed: 21504792]

Metabolism of *L*-Glutamate

Figure 1.
Regulation of brain GABA concentration

Figure 2.
Crystal structure of GABA-AT inactivated by vigabatrin (brown)

Figure 3.
(A) Energy minimized molecular model of vigabatrin bound to PLP in GABA-AT. (B) Model showing necessary bond rotation for proper alignment to allow Michael addition to occur; Lys-329 set up for both Michael addition and enamine formation

Figure 4.
Conformationally-rigid vigabatrin analog with the methylene group oriented toward Lys-329 for rapid reaction

Figure 5.

(**A**) Time-dependent effect of **15** on alanine aminotransferase. (**B**) Concentration-dependent effect of **15** on alanine aminotransferase.

Figure 6.

Effect of vigabatrin and **15** on dopamine release by cocaine in freely moving rats. Cocaine was administered at 20 mg/kg.

Figure 7.

In vivo microPET imaging of [^{11}C]-raclopride (red color, baseline panel). Administration of 20 mg/kg of cocaine leads to the release of dopamine, which displaces the [^{11}C]-raclopride (middle panel). Administration of 20 mg/kg of cocaine and 0.5 mg/kg of **15** does not release [^{11}C]-raclopride (right panel).

Scheme 1.
Mechanism of GABA-AT

Scheme 2.
Mechanism of inactivation of GABA-AT by vigabatrin

Scheme 3.
Michael addition pathway (a) and enamine pathway (b) for **10**

Table 1

Compound **15** alone is not rewarding and blocks the expression of place preference to cocaine (20 mg/kg). **15** (1 mg/kg) and vigabatrin (300 mg/kg) produced comparable inhibition of cocaine-induced place preference, $p < 0.001$, Student's t-test

Treatment Group	Number of animals	Time in chamber (min)	
		Paired with cocaine	Unpaired with cocaine
Saline/Saline	9	7.3 ± 0.5	7.7 ± 0.6
Saline/Cocaine	9	11.8 ± 0.4	3.2 ± 0.4
Saline/ 15	8	8.1 ± 0.2	6.9 ± 0.9
15 /Cocaine	8	7.8 ± 0.5	7.2 ± 0.9
Vigabatrin/Cocaine	10	7.9 ± 0.5	7.1 ± 0.6